Explore

Trendline Trendline
Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations

Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations

Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations
Trendline Trendline
Kivu Bioscience Appoints Mohit Trikha as CEO to Drive Oncology Advancements

Kivu Bioscience Appoints Mohit Trikha as CEO to Drive Oncology Advancements

Kivu Bioscience Appoints Mohit Trikha as CEO to Drive Oncology Advancements
Trendline Trendline
Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting

Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting

Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with Dual-Payload ADCs

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with Dual-Payload ADCs

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with Dual-Payload ADCs
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with ADC Technology

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with ADC Technology

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with ADC Technology
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities

Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities

Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Kivu Bioscience to Showcase ADC Innovations at AACR Annual Meeting 2026

Kivu Bioscience to Showcase ADC Innovations at AACR Annual Meeting 2026

Kivu Bioscience to Showcase ADC Innovations at AACR Annual Meeting 2026
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth

Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth

Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth
Trendline Trendline
Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
CrossBridge Bio Acquired by Eli Lilly to Advance Cancer Treatment Technology

CrossBridge Bio Acquired by Eli Lilly to Advance Cancer Treatment Technology

CrossBridge Bio Acquired by Eli Lilly to Advance Cancer Treatment Technology
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal